How ulcerative colitis medicines affect blood vessel stiffness
Part of Digestive system clinical trials.
This study looks at how common ulcerative colitis treatments (anti-TNF medicines, vedolizumab, or tofacitinib) change the health of your blood vessels. It may help doctors better understand cardiovascular risk in people with ulcerative colitis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ulcerative colitis for at least 6 months
- You are 18 years or older
- You are starting a specific ulcerative colitis medicine: infliximab, adalimumab, golimumab, vedolizumab, or tofacitinib
- You can sign a consent form and agree to join
- Your blood pressure, aspirin/antiplatelet, and cholesterol medicines (if you take them) must be at a stable dose for the past 3 months and during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how tofacitinib (and related medicines) may affect clotting and blood-platelet function, and whether this could relate to blood clot risk. It includes detailed blood and stool/colonoscopy-related testing in adults with ulcerative colitis and in some people without it.
This trial tests if combining two medicines, vedolizumab and tofacitinib, helps control moderate to severe ulcerative colitis. It may be an option if other treatments, like anti-TNF drugs, haven't worked well for you.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
This study builds a prediction model to estimate how people with ulcerative colitis may respond to certain medicines. It may help doctors choose the most effective treatment sooner.
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
This trial tests whether vedolizumab helps people with moderate-to-severe ulcerative colitis and what changes happen in the gut microbiome (the community of helpful bacteria in your intestines). You may be able to join if you’re an adult with ulcerative colitis who has not used vedolizumab before and haven’t taken certain gut-affecting medicines recently.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.